Combining metabolic phenotype determination with metabolomics and transcriptional analyses to reveal pathways regulated by hydroxycarboxylic acid receptor 2.
Cancer metabolism
GPR109A
HCA2
LC-MS
Metabolite profile
Metabolite-sensing GPCR
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
13 Jun 2022
13 Jun 2022
Historique:
received:
13
04
2022
accepted:
20
05
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
The adaptation of cellular metabolism is considered a hallmark of cancer. Oncogenic signaling pathways support tumorigenesis and cancer progression through the induction of certain metabolic phenotypes associated with altered regulation of key metabolic enzymes. Hydroxycarboxylic acid receptor 2 (HCA We performed both, siRNA mediated knockdown of HCA Knockdown or stimulation of HCA We combined metabolic phenotype determination with metabolomics and transcriptional analyses and identified HCA
Sections du résumé
BACKGROUND
BACKGROUND
The adaptation of cellular metabolism is considered a hallmark of cancer. Oncogenic signaling pathways support tumorigenesis and cancer progression through the induction of certain metabolic phenotypes associated with altered regulation of key metabolic enzymes. Hydroxycarboxylic acid receptor 2 (HCA
METHODS
METHODS
We performed both, siRNA mediated knockdown of HCA
RESULTS
RESULTS
Knockdown or stimulation of HCA
CONCLUSIONS
CONCLUSIONS
We combined metabolic phenotype determination with metabolomics and transcriptional analyses and identified HCA
Identifiants
pubmed: 35697980
doi: 10.1007/s12672-022-00503-3
pii: 10.1007/s12672-022-00503-3
pmc: PMC9192902
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 407707190
Informations de copyright
© 2022. The Author(s).
Références
Annu Rev Nutr. 2017 Aug 21;37:51-76
pubmed: 28826372
J Biol Chem. 2005 Jul 22;280(29):26649-52
pubmed: 15929991
Metabolism. 2016 Feb;65(2):102-13
pubmed: 26773933
Cells. 2020 Oct 16;9(10):
pubmed: 33081387
Oncotarget. 2015 Aug 14;6(23):19706-20
pubmed: 25839160
Annu Rev Biomed Eng. 2017 Jun 21;19:163-194
pubmed: 28301735
Cells. 2020 Oct 23;9(11):
pubmed: 33113952
PLoS Genet. 2019 May 23;15(5):e1008145
pubmed: 31120900
Trends Biochem Sci. 2017 Apr;42(4):274-284
pubmed: 28196646
J Lipid Res. 2009 May;50(5):908-14
pubmed: 19136666
Cancer Cell Int. 2019 Jun 18;19:165
pubmed: 31244553
Nat Rev Mol Cell Biol. 2019 Jun;20(6):353-367
pubmed: 30814649
Cancer Res. 2014 Feb 15;74(4):1166-78
pubmed: 24371223
Sci Rep. 2021 Mar 15;11(1):6047
pubmed: 33723286
Nat Commun. 2020 Jan 3;11(1):102
pubmed: 31900386
Cancers (Basel). 2021 Feb 22;13(4):
pubmed: 33671514
Trends Pharmacol Sci. 2019 Jun;40(6):378-387
pubmed: 31078319
Cancer Lett. 2015 Jan 28;356(2 Pt A):184-91
pubmed: 24508027
Cancer Res. 2009 Apr 1;69(7):2826-32
pubmed: 19276343
Diabetes. 2006 May;55(5):1270-5
pubmed: 16644682
Cell Rep. 2017 Jan 17;18(3):647-658
pubmed: 28099844
Pharmacogenomics. 2019 Nov;20(16):1143-1150
pubmed: 31617441
Br J Pharmacol. 2013 Mar;168(5):1266-78
pubmed: 23072560
Metabolomics. 2016;12:146
pubmed: 27616976
Cancer Lett. 2022 Feb 1;526:91-102
pubmed: 34813893
Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5
pubmed: 18722346
Oncogene. 2006 Aug 7;25(34):4633-46
pubmed: 16892078
J Biol Chem. 2010 Aug 27;285(35):27418-27428
pubmed: 20558738
Front Pharmacol. 2018 Mar 09;9:128
pubmed: 29593527
CA Cancer J Clin. 2021 Jul;71(4):333-358
pubmed: 33982817
Exp Dermatol. 2018 Jun;27(6):611-624
pubmed: 29603404
Food Chem. 2019 Sep 30;293:537-544
pubmed: 31151645
Cancer Cell. 2006 Jun;9(6):425-34
pubmed: 16766262